Brief: Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase Degrader Programs, NX-5948 and NX-2127
11/12/2023 17:53
Dec 11 (Reuters) - Nurix Therapeutics Inc NRIX.O :
* NURIX THERAPEUTICS PRESENTS POSITIVE CLINICAL DATA FROM
ITS
NOVEL BRUTON’S TYROSINE KINASE (BTK) DEGRADER PROGRAMS, NX-5948
AND NX-2127, AT THE 65TH AMERICAN SOCIETY OF HEMATOLOGY (ASH)
ANNUAL MEETING
* NURIX THERAPEUTICS INC - POSITIVE PRELIMINARY EFFICACY
DATA WITH
A FAVORABLE SAFETY PROFILE SUPPORT PLANS TO DEVELOP NX-5948
BROADLY IN CLL
Source text for Eikon: ID:nGNX6DySD7
Further company coverage: NRIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis